Zepbound: Medical Uses and Indications
Critical Information: Evidence Mismatch
The provided evidence does not contain any information about Zepbound. All references in the evidence base pertain to tuberculosis medications (ethambutol, cycloserine, ethionamide, streptomycin, and fixed-dose combinations like Rifamate® and Rifater®) 1 or zilucoplan (a complement C5 inhibitor) 2, 3, 4, 5, 6. None of these medications are Zepbound.
What Zepbound Actually Is (Based on General Medical Knowledge)
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition, used in conjunction with a reduced-calorie diet and increased physical activity.
Primary Indication
- Chronic weight management in adults meeting specific BMI criteria with weight-related health conditions such as:
- Type 2 diabetes mellitus
- Hypertension
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
Mechanism of Action
- Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
- Administered as a once-weekly subcutaneous injection
- Promotes weight loss through appetite suppression, delayed gastric emptying, and improved glycemic control
Dosing Strategy
- Initiated at 2.5 mg subcutaneously once weekly for 4 weeks
- Titrated upward in 2.5 mg increments every 4 weeks as tolerated
- Maximum maintenance dose: 15 mg once weekly
Important Clinical Caveat
This response is based on general medical knowledge only, as the evidence provided does not address Zepbound. For definitive prescribing information, clinical guidance, contraindications, and safety monitoring parameters, consult the official FDA-approved prescribing information for Zepbound (tirzepatide) and current endocrinology or obesity medicine guidelines.